Latest news with #KennethCuster
Business Insider
20 hours ago
- Health
- Business Insider
Tests Show Eli Lilly's (LLY) Weight-Loss Pill Works as Well as Injection
Preliminary test results show that Eli Lilly's (LLY) daily weight-loss pill, called Orforglipron, is as effective as the company's injectable GLP-1 drug Zepbound. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. The weight-loss pill from Eli Lilly is also equally good at lowering blood sugar levels in people with diabetes, according to new data from a Phase 3 clinical trial. The results were announced at the annual meeting of the American Diabetes Association and the findings published in the prestigious New England Journal of Medicine. Pharmaceutical giant Eli Lilly currently makes the blockbuster drug Mounjaro for Type 2 diabetes and Zepbound for weight management. Like rival Novo Nordisk's (NVO) Ozempic and Wegovy, both of Eli Lilly's drugs are injected by people on a weekly basis. However, a weight-loss pill is widely viewed as a potential gamechanger given many people's fear of needles and difficulty injecting themselves. Race for the Pill Eli Lilly, Novo Nordisk, and other pharmaceutical companies are racing to bring a weight-loss pill to market. Eli Lilly's Orforglipron pill is currently in late stage clinical trials and could be approved by the U.S. Food and Drug Administration (FDA) in 2026, though an exact date is not yet known. So far, preliminary data on Eli Lilly's pill to help manage obesity is showing promising results. 'What we see is that the efficacy, safety, and tolerability are really consistent with the very best injectable (medications),' said Kenneth Custer, President of Cariometabolic Health at Eli Lilly, in a news release concerning the company's experimental pill. 'We think this is a big deal.' Is LLY Stock a Buy? The stock of Eli Lilly has a consensus Strong Buy recommendation among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $999.57 implies 28.83% upside from current levels.
Indian Express
23-06-2025
- Health
- Indian Express
Eli Lilly's new oral weight loss pill works as well as injectables: Why this could be better than oral semaglutide?
The blockbuster weight loss drug, semaglutide, now has competition in orforglipron, which is just as safe as injectable alternatives and more effectively lowers HbA1c (average blood sugar count of three months) in patients with type 2 diabetes and obesity. The best part. No injections required — just a daily pill. The investigational once-daily pill by US manufacturer Eli Lilly lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes, according to Phase 3 results of the ACHIEVE-1 trials, published in The New England Journal of Medicine. Orforglipron also led to an average weight loss of 16.0 lbs or 7.3 kg (7.9%) at the highest dose by week 40. 'The efficacy, safety, and tolerability are really consistent with the very best injectable GLP-1s,' Kenneth Custer, president of cardiometabolic health at Eli Lilly, was quoted as saying. Why is orforglipron effective? Orforglipron and semaglutide are both GLP-1 receptor agonists, which mimic the effects of the naturally occurring hormone GLP-1, which helps regulate blood sugar, reduce appetite and slow down gastric emptying. But while orforglipron is non-peptide, semaglutide is a peptide. Peptides are smaller than proteins, while non-peptides encompass a wider range of chemical compounds with diverse structures and functions. 'Orforglipron, being a non-peptide, is a smaller molecule. This allows better absorption of the drug through the gut. They don't get broken down as easily by digestive enzymes. Hence the efficacy,' says Dr Anoop Misra, chairman, diabetes and endocrinology, Fortis C-Doc. What are the advantages of orforglipron over semaglutide? Orforglipron is an oral pill taken once daily, while semaglutide is available as both an oral tablet (Rybelsus) and a subcutaneous injection (Ozempic, Wegovy). 'Previous oral GLP-1s like semaglutide (Rybelsus) are peptide-based and have significant limitations — they must be taken on an empty stomach with minimal water and have much lower bioavailability than injectable form. Orforglipron is a small molecule that doesn't require food or water restrictions, so it is very convenient and is absorbed easily,' says Dr Misra. What about the trial results? At 40 weeks, all three doses (3 mg, 12 mg, 36 mg) of orforglipron achieved the primary goal of superior HbA1C reduction. Improvements in HbA1C were observed as early as four weeks and were accompanied by similar reductions in fasting serum glucose. 'The early onset of glycemic improvement, observed as soon as four weeks, reinforces the therapeutic potential of orforglipron as an effective, oral GLP-1 therapy for early type 2 diabetes treatment. These findings support further investigation in broader populations and longer-duration studies,' said Dr Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine, University of Texas Southwestern Medical Center, and lead trial investigator. What about side effects? In the study, orforglipron had a safety profile similar to the established GLP-1 class of medication. The most frequently reported adverse events were gastrointestinal-related.
Cision Canada
13-05-2025
- Health
- Cision Canada
LILLY CANADA ANNOUNCES AVAILABILITY OF MOUNJARO® KWIKPEN® (TIRZEPATIDE INJECTION) IN ALL DOSES, ADVANCING CARE FOR ADULTS LIVING WITH TYPE 2 DIABETES Français
The multi-dose, single-patient-use, prefilled pen allows for personalized treatment plans that can cater to individual patient needs , May 13, 2025 /CNW/ - Lilly Canada is pleased to announce that Mounjaro ® KwikPen ® (tirzepatide injection) is now available in Canada in all doses, offering a convenient treatment option for adults with type 2 diabetes. Mounjaro ® is the first and only Health Canada-authorized once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. 1 Mounjaro ® KwikPen ® is a multi-dose single-patient-use prefilled pen. Each Mounjaro ® KwikPen ® contains four fixed doses of 0.6 mL, each dose taken once weekly. 2 It is available in six different dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), 3 providing healthcare providers with the ability to personalize treatment plans to better meet individual patient needs. "The availability of all doses of Mounjaro KwikPen represents a significant step forward for people living with type 2 diabetes," says Dr. Akshay Jain, Clinical and Research Endocrinologist in Surrey, BC. "The KwikPen may help support greater convenience when traveling and may help reduce the risk of dosing errors, making type 2 diabetes management less burdensome for patients." Over 5 million adults are living with diabetes in Canada, of which 90 per cent of the cases are type 2 diabetes. 4 If left unmanaged, this chronic disease can lead to heart attacks, strokes, kidney failure, and blindness, and could reduce lifespan by five to 15 years. 5 The launch of Mounjaro ® KwikPen ® represents a step forward in type 2 diabetes care, offering a convenient way for patients to administer their medication. "Lilly Canada is dedicated to providing innovative medicines that create positive impacts in the lives of Canadians and help reduce the burden on our healthcare system," says Kenneth Custer, Lilly Canada President and General Manager. "Mounjaro represents an important advancement for people with type 2 diabetes and Mounjaro KwikPen will allow us to meet the future demand for this medicine in Canada." Mounjaro ® KwikPen ® is now available by prescription across Canada. Patients should consult with their healthcare provider to determine if Mounjaro ® KwikPen ® is the right treatment option for them. About Mounjaro ® (tirzepatide) injection 5 Mounjaro ® (tirzepatide) is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As the first and only Health Canada-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). To view the full Mounjaro ® product monograph, please visit Lilly is committed to helping people access the medicines they are prescribed, and will work with insurers, health systems and providers to help enable patient access to Mounjaro. Lilly offers a Patient Support Program for eligible patients. Patients or healthcare professionals with questions about Mounjaro can visit or call the Lilly Customer Response Centre at 1-888-545-5972. About Lilly Canada Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism. Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at SOURCE Eli Lilly Canada Inc.
Yahoo
08-05-2025
- Business
- Yahoo
Eli Lilly (NYSE:LLY) Announces Executive Changes To Drive Global Growth And Pipeline Advancement
Eli Lilly recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and Kenneth Custer, marking a strategic shift aiming to expand its global market presence and enhance product reach. Over the past month, the company's stock appreciated by 7%, potentially reflecting investor confidence in its direction amid these changes. Strong quarterly financial results, with significant increases in sales and earnings, would have bolstered investor sentiment. While broader market trends showed an upward trajectory with the Dow Jones and S&P 500 also rising, Eli Lilly's comprehensive developments likely added weight to its favorable performance. We've identified 2 possible red flags with Eli Lilly (at least 1 which is a bit concerning) and understanding the impact should be part of your investment process. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Eli Lilly's recent leadership transitions could bolster its strategic focus on global market expansion, potentially impacting its revenue and earnings forecasts. The company aims to enhance its product reach, particularly in oncology and immunology, areas of anticipated growth based on the release of Phase III trial data. These developments are positioned against the backdrop of significant investments in manufacturing and R&D, which could optimize production efficiency and improve supply chain resilience, key factors for revenue growth despite potential short-term costs. Looking at its longer-term performance, Eli Lilly's stock appreciated by 422.93% over the past five years, reflecting substantial growth compared to the US Pharmaceuticals industry. Over the past year, while the industry experienced a shrinkage of 7.3%, Eli Lilly managed to outperform this trend with notable performance this must be viewed in the context of a broader market comparison over the same period where the US market saw a return of 7.7%, meaning Eli Lilly's performance was not as strong in that specific timeframe. The recent 7% share price increase, amid expectations of revenue reaching US$85.1 billion and earnings climbing to US$31.7 billion by 2028, indicates investor positivity. Analysts' consensus price target of US$981.63 suggests a 21% potential increase from the current share price of US$775.12, though it's essential for investors to analyze these figures alongside potential risks such as pricing pressures and regulatory challenges. Prudence is advised when considering the alignment of actual future outcomes with these optimistic forecasts. Click here to discover the nuances of Eli Lilly with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
